📊 IOSP Key Takeaways
Is Innospec Inc.. (IOSP) a Good Investment?
Innospec demonstrates solid financial health with exceptional liquidity (2.79x current ratio), zero long-term debt, and strong free cash flow generation ($120.7M). While revenue declined 3.7% YoY, the dramatic 227.5% net income surge indicates significant operational leverage and margin improvement, though sustainability of this exceptional earnings growth requires scrutiny.
Innospec shows solid fundamental quality through a debt-free balance sheet, strong liquidity, and consistent free cash flow generation. However, revenue declined year over year and the large jump in net income appears much stronger than operating profit growth, which raises some caution on earnings quality and the durability of recent profit improvement. The company looks financially healthy, but fundamental momentum is not strong enough to justify a more aggressive rating.
Why Buy Innospec Inc.. Stock? IOSP Key Strengths
- Zero long-term debt with $292.5M cash provides financial flexibility and fortress balance sheet
- Exceptional free cash flow conversion (6.8% FCF margin on declining revenue) demonstrates efficient capital management
- Net income growth of 227.5% YoY with EPS up 228.9% suggests operational turnaround and margin expansion
- Strong liquidity position (2.79x current ratio, 1.88x quick ratio) ensures operational stability
- Debt-free balance sheet with $292.5M in cash and no long-term debt
- Healthy liquidity profile with 2.79x current ratio and 1.88x quick ratio
- Positive free cash flow of $120.7M with solid cash generation relative to earnings
IOSP Stock Risks: Innospec Inc.. Investment Risks
- Revenue decline of 3.7% YoY in cyclical chemicals sector raises concerns about end-market demand and competitive position
- Net margin of only 6.6% and operating margin of 7.3% are modest for a company claiming significant operational improvement
- Exceptional earnings growth appears anomalous relative to flat/declining revenue, suggesting one-time items or unusual gains requiring validation
- High insider trading activity (27 Form 4 filings in 90 days) warrants investigation for potential signaling concerns
- Revenue declined 3.7% year over year, indicating weak top-line momentum
- Net income grew far faster than operating income, suggesting possible non-operating or non-recurring earnings support
- Profitability is positive but still moderate, with 7.3% operating margin and 8.8% ROE
Key Metrics to Watch
- Revenue growth trajectory and segment-level performance to confirm end-market stabilization
- Sustainability of margin improvements and verification of earnings quality (operating vs. non-operating gains)
- Capital expenditure trends and R&D spending to assess competitive investment levels
- Working capital efficiency and free cash flow consistency in subsequent quarters
- Revenue growth and segment demand recovery
- Operating margin and free cash flow conversion
Innospec Inc.. (IOSP) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.79x current ratio provides a solid financial cushion.
IOSP Profit Margin, ROE & Profitability Analysis
IOSP vs Materials Sector: How Innospec Inc.. Compares
How Innospec Inc.. compares to Materials sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Innospec Inc.. Stock Overvalued? IOSP Valuation Analysis 2026
Based on fundamental analysis, Innospec Inc.. has mixed fundamental signals relative to the Materials sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Innospec Inc.. Balance Sheet: IOSP Debt, Cash & Liquidity
IOSP Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Innospec Inc..'s revenue has grown significantly by 29% over the 5-year period, indicating strong business expansion. The most recent EPS of $5.56 reflects profitable operations.
IOSP Revenue Growth, EPS Growth & YoY Performance
IOSP Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $441.9M | $12.9M | $0.52 |
| Q2 2025 | $435.0M | $23.5M | $0.94 |
| Q1 2025 | $440.8M | $32.8M | $1.31 |
| Q3 2024 | $443.4M | $33.4M | $1.33 |
| Q2 2024 | $435.0M | $28.9M | $1.16 |
| Q1 2024 | $500.2M | $33.2M | $1.33 |
| Q3 2023 | $464.1M | $38.7M | $1.55 |
| Q2 2023 | $467.6M | $28.9M | $1.16 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Innospec Inc.. Dividends, Buybacks & Capital Allocation
IOSP SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Innospec Inc.. (CIK: 0001054905)
📋 Recent SEC Filings
❓ Frequently Asked Questions about IOSP
What is the AI rating for IOSP?
Innospec Inc.. (IOSP) has a Combined AI Rating of BUY from Claude (BUY) and ChatGPT (HOLD) with 74% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are IOSP's key strengths?
Claude: Zero long-term debt with $292.5M cash provides financial flexibility and fortress balance sheet. Exceptional free cash flow conversion (6.8% FCF margin on declining revenue) demonstrates efficient capital management. ChatGPT: Debt-free balance sheet with $292.5M in cash and no long-term debt. Healthy liquidity profile with 2.79x current ratio and 1.88x quick ratio.
What are the risks of investing in IOSP?
Claude: Revenue decline of 3.7% YoY in cyclical chemicals sector raises concerns about end-market demand and competitive position. Net margin of only 6.6% and operating margin of 7.3% are modest for a company claiming significant operational improvement. ChatGPT: Revenue declined 3.7% year over year, indicating weak top-line momentum. Net income grew far faster than operating income, suggesting possible non-operating or non-recurring earnings support.
What is IOSP's revenue and growth?
Innospec Inc.. reported revenue of $1.8B.
Does IOSP pay dividends?
Innospec Inc.. pays dividends, with $42.4M distributed to shareholders in the trailing twelve months.
Where can I find IOSP SEC filings?
Official SEC filings for Innospec Inc.. (CIK: 0001054905) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is IOSP's EPS?
Innospec Inc.. has a diluted EPS of $4.67.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is IOSP a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Innospec Inc.. has a BUY rating with 74% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is IOSP stock overvalued or undervalued?
Valuation metrics for IOSP: ROE of 8.8% (sector avg: 14%), net margin of 6.6% (sector avg: 10%). Compare these metrics with sector averages to assess valuation.
Should I buy IOSP stock in 2026?
Our dual AI analysis gives Innospec Inc.. a combined BUY rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is IOSP's free cash flow?
Innospec Inc..'s operating cash flow is $138.3M, with capital expenditures of $17.6M. FCF margin is 6.8%.
How does IOSP compare to other Materials stocks?
Vs Materials sector averages: Net margin 6.6% (avg: 10%), ROE 8.8% (avg: 14%), current ratio 2.79 (avg: 1.6).